Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper – Head and neck cancer

3250 - Personalized treatment according to geriatric assessment in 1st line recurrent and/or metastatic (R/M) Head and Neck Squamous Cell Cancer (HNSCC) patients aged 70 or over. ELAN (ELderly heAd and Neck cancer) FIT and UNFIT trials


30 Sep 2019


Proffered Paper – Head and neck cancer


Tumour Site

Head and Neck Cancers


Joel Guigay


Annals of Oncology (2019) 30 (suppl_5): v449-v474. 10.1093/annonc/mdz252


J. Guigay1, A. Auperin2, C. Mertens3, C. Even4, L. Geoffrois5, D. Cupissol6, F. Rolland7, C. Sire8, J. Fayette9, F. Peyrade1, E. Blot10, P. Debourdeau11, L. Bozec12, O. Capitain13, Y. Pointreau14, C. Brard15, C. Michel16, D. Schwob15, C. Ortholan17, H. Le Caer18

Author affiliations

  • 1 Medical Oncology, Centre Antoine Lacassagne, Université Côte d'Azur, 6100 - Nice/FR
  • 2 Biostatistics, Gustave Roussy, 94805 - Villejuif/FR
  • 3 Medical Oncology, Institute Bergonié, 33076 - Bordeaux/FR
  • 4 Department Of Head And Neck Oncology, Gustave Roussy, 94805 - Villejuif/FR
  • 5 Medical Oncology, Institut de Cancérologie de Lorraine - Alexis Vautrin, 54519 - Vandoeuvre les Nancy/FR
  • 6 Oncologie Medicale, Institut régional du cancer de Montpellier, Montpellier/FR
  • 7 Oncologie Medicale, ICO Institut de Cancerologie de l'Ouest René Gauducheau, 44805 - Saint-Herblain/FR
  • 8 Radiation Oncology, Centre Hospitalier de Bretagne Sud - Hôpital du Scorff, 56322 - Lorient/FR
  • 9 Medical Oncology, Centre Léon Bérard, 69008 - Lyon/FR
  • 10 Oncologie Medicale, Centre d'Oncologie St. Yves, 56000 - Vannes/FR
  • 11 Oncology, Institut Ste Catherine, 84082 - Avignon/FR
  • 12 Oncologie Medicale, Institut Curie – Hôpital René Huguenin, Saint-Cloud/FR
  • 13 Oncologie Medicale, Centre Paul Papin, 49055 - Angers/FR
  • 14 Radiation Oncology, Institut Inter-régionaL de Cancérologie-Centre Jean Bernard-Clinique Victor Hugo, 72000 - Le Mans/FR
  • 15 Biostatistic And Epidemiology Unit, Gustave Roussy Cancer Campus, 94800 - Villejuif/FR
  • 16 Clinical Research, GORTEC, TOURS/FR
  • 17 Service De Radiotherapie, Centre Hospitalier Princesse Grace, Monaco/MC
  • 18 Service De Pneumologie, Hôpital Yves Le Foll, Centre Hospitalier de Saint-Brieuc, 22027 - Saint Brieuc/FR


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 3250


The main challenges in patients (pts) > = 70y are to cope with the treatment benefit/risk ratio and tumor related symptoms; no standard systemic treatment has been validated. With GERICO-GORTEC groups, we developed a large prospective clinical program named ELAN to improve the management of elderly HNSCC using an adapted geriatric evaluation feasible in daily practice and to set new standards of care for these pts. We report the results of ELAN FIT and UNFIT trials dedicated to elderly R/M HNSCC pts.


To be included in one of the 2 trials, 1st line R/M SCCHN pts > = 70y must first be enrolled in ELAN-ONCOVAL study where they were classified as fit or unfit, using the ELAN geriatric evaluation (EGE). Comprehensive Geriatric Assessment was optional. Fit pts were proposed to be enrolled in the 2-stage phase II ELAN-FIT trial, which evaluated the cetuximab-carboplatin-5FU (EXTREME) combination in terms of efficacy (objective response at 12 weeks) and safety assessed by lack of grade > =4 toxicity and lack of loss of independence. Unfit pts were proposed to be enrolled in the randomized phase III ELAN-UNFIT trial, that compared 2 monotherapies, cetuximab (Cx) 500 mg/m² every 2 weeks versus weekly methotrexate (MTX) 40 mg/m² in terms of failure free survival (failures are progression, treatment stop, loss > = 2 points in Activities in Daily Living scale or death).


160 pts were enrolled in the trials. The UNFIT trial was stopped after futility analysis. Main results are shown in the table.Table: 1110O

ELAN-FIT trialELAN-UNFIT trial N = 82
Carbo-5FU-cetux (n = 78)CX arm (n = 41)MTX arm (n = 41)Pts PS ECOG 0-1 (n = 47) (2 arms together)Pts PS ECOG 2 (n = 35) (2 arms together)
Adverse events > =grade 424%27%22%13%40%
Objective response rateAt W12: 38% (central review)12%15%13%14%
OS median (months)14.7 (95%CI=11.0-18.2)4.6 (95%CI=2.4-7.3)4.6 (95%CI=2.3-7.7)7.3 (95%CI=4.6-9.6)2.1 (95%CI=1.5-3.2)
1-year OS rate58% (95%CI=46%-68%)22.5% (95% CI=12.3%-37.5%)14.6% (95% CI=6.9%-28.4%)27.7% (95% CI=16.9%-41.8%)5.9% (95% CI=1.6%-19.1%)
PFS median (months)7.1 (95%CI=5.5-8.2)2.4 (95%CI=1.5-3.8)2.8 (95%CI=1.6-4.2)3.8 (95%CI=2.6-5.5)1.5 (95%CI=1.2-2.3)
1-year PFS rate24.5% (95%CI=15.5%-34.6%)7.5% (95% CI=2.6%-19.9%)7.3% (95% CI=2.5%-19.4%)12.8% (95% CI=6.0%-25.2%)0%


Fit elderly pts as selected using EGE, benefited from carboplatin based EXTREME regimen, with promising overall survival (OS), which compares favourably with that of younger pts. For unfit elderly pts, there was no efficacy difference of Cx and MTX. PS ECOG 2 pts did not benefit from systemic treatment. New therapeutic options should be explored for ECOG 0-1 unfit elderly pts.

Clinical trial identification

ELAN-UNFIT: NCT01884623 ELAN-FIT: NCT01864772.

Editorial acknowledgement

Legal entity responsible for the study

Gustave Roussy and GORTEC.




J. Guigay: Advisory / Consultancy: AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: BMS; Advisory / Consultancy: Innate Pharma; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Merck. C. Even: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: BMS; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Merck; Advisory / Consultancy, Travel / Accommodation / Expenses: MSD; Advisory / Consultancy: Innate Pharma. L. Geoffrois: Honoraria (self), Travel / Accommodation / Expenses: BMS; Honoraria (self), Travel / Accommodation / Expenses: MSD; Honoraria (self): Ipsen; Honoraria (self): Novartis; Travel / Accommodation / Expenses: Merck Serono. C. Sire: Travel / Accommodation / Expenses: Merck. J. Fayette: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: BMS; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: MSD; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Advisory / Consultancy: Merck; Honoraria (self), Advisory / Consultancy: Innate; Honoraria (self), Advisory / Consultancy: Biogen. F. Peyrade: Advisory / Consultancy: MSD; Advisory / Consultancy: Merck. P. Debourdeau: Non-remunerated activity/ies: Pfizer; Honoraria (self): Leo Pharma; Honoraria (self): Bayer. Y. Pointreau: Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: Merck; Honoraria (self), Advisory / Consultancy: MSD. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.